KURA commercial momentum and late-stage pipeline seen advancing toward 2028
Komz?fti’s commercial launch is exceeding expectations, with strong revenue growth, majority market share in NPM1 mutant AML, and broad payer coverage. Multiple late-stage studies are progressing, with key data readouts and potential accelerated approvals targeted for 2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.